18463 RESULTS
THERAPEUTICS Nura Bio™ Inc. Small Molecule Other In August 2023, Nura Bio began Phase 1 with an ascending-dose safety trial in 66 healthy volunteers. Single doses of 50, 100, 175, 300, 450, and 600 mg, or 10 days of repeated dosing were compared to placebo. Besides sa
COMMENT A PET ligand that reveals oxidative stress in the human brain will facilitate work within the AD research field on a number of levels. It will help investigators get a glimpse into oxidative stress in the brains of AD patients. From there, investigators c
, United Kingdom
PAPER Wen S, Ju Z, Wang Y, Zuo CT, Sun X, Zheng T
PAPER Ludolph A, Klose V, Dreyhaupt J, Del Tredici K, Braak H
PAPER Al-Kuraishy HM, Sulaiman GM, Mohammed HA, Al-Gareeb AI, Albuhadily AK, Mohammed SG
PAPER Preziuso A, Serfilippi T, Toujani M, Terenzi V, Amoroso S, Magi S, Lariccia V, Piccirillo S
PAPER Qiang Q, Skudder-Hill L, Toyota T, Huang Z, Wei W, Adachi H, Alzheimer’s Disease Neuroimaging Initiative
PAPER Pikija S, Toma A, Radlberger R, Griessenauer CJ, Hecker C, Trinka E, Ki PH, Kraus T, Weis S, Wermer MJ, van Etten ES, Kaushik K
PAPER Alpaugh M, Lantero-Rodriguez J, Benedet AL, Manseau U, Boutin M, Maiuri M, Denis HL, Masnata M, Fazal SV, Chouinard S, Rosa-Neto P, Barker RA, Blennow K, Zetterberg H, Labib R, Cicchetti F
PAPER Wang Z, Cheng C, Duan H, Chen X, Li W, Ma F, Li Z, Yan J, He R, Li Z, Yang M, Huang Z, Chen Y, Huang G
PAPER Antonioni A, Raho EM, Di Lorenzo F, Manzoli L, Flacco ME, Koch G
PAPER Li B, Zeng B, Zeng P, Luo D, Peng Y, Zhu Q, Yan Z, Chai Y, Nie L, Wang D, Xiang Y, Li Y
PAPER Reumers SF, Bongaerts FL, de Leeuw FE, van de Warrenburg BP, Schutter DJ, Kessels RP
PAPER Liao Y, Chong JR, Kan CN, Zhao X, Chai YL, Hilal S, Lai MK, Chen CP, Xu X
